The 27 mg dose was most effective in the phase 2a. trial.....9 mg dose was not so effective. (this tends to t support exactly what they are saying now)
Print page AOD9604 Obesity drug oral Phase 2A Human Clinical Trial Document date: Tue 27 Aug 2002 POSITIVE RESULTS FROM AOD9604 OBESITY DRUG ORAL PHASE 2A HUMAN CLINICAL TRIAL
Metabolic is very pleased to announce the successful completion of its Phase 2A human clinical trial of obesity drug AOD9604 by single-dose oral administration, showing positive results.
"all dose levels of AOD9604 (9, 27 and 54 mg) lasting several hours after administration, reaching statistical significance at 27 mg. Fat breakdown, a signal of drug activity, is followed in the blood by measuring levels of non-esterified fatty acids (NEFA). TRIAL DESIGN AND RESULTS
The double-blind trial was conducted in 16 clinically obese but otherwise healthy male volunteers aged 35 to 60. Each received the following single oral doses of AOD9604 in random order: placebo (0), 9, 27 or 54 mg. Each dose was separated by an interval of 2 weeks.
However the most active fat breakdown dose (27 mg) resulted in the greatest average weight change one week after dose, a reduction of 0.2 kg relative to placebo.
MBP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
